• Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
    • Scientific
    • Investors
    • Veterinary Resources
  • Join Mailing List
Volition
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
Volition
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
      • Press Releases
      • Video Gallery
      • Media Toolkit
      • Downloads
    • Scientific
      • Clinical Papers & Posters
      • Presentations
      • Video Gallery
    • Investors
      • Presentations
      • Video Gallery
    • Veterinary Resources
  • Join Mailing List

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Shareholders Letters
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Shareholders Letters
  • IR Calendar
  • Presentations
  • Email Alerts
May 13, 2016 7:00am EDT

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

May 12, 2016 7:00am EDT

VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer

May 09, 2016 7:00am EDT

VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET

Apr 20, 2016 9:00am EDT

VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test

Apr 14, 2016 7:00am EDT

VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer

Apr 11, 2016 7:00am EDT

VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series

Apr 08, 2016 7:00am EDT

VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study

Apr 07, 2016 7:08am EDT

VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer

Mar 23, 2016 11:30am EDT

VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full

Mar 18, 2016 9:29am EDT

VolitionRx Announces Pricing of Public Offering of Common Stock

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Contact Us
  • Downloads
  • Privacy Policy
  • Disclaimer
  • Manage Cookie Preferences
Sign up to  email alerts
linkedin facebook twitter
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard

MENAC - Epigenetic Modifications of Nucleosomes Associated with Cancer

Thanks to a grant of 1.990.798€ from the European Regional Development Fund and Walloon Government, we’re taking part in the MENAC project which aims to develop innovative non-invasive tests for the early detection of different types of cancer. We’re working in partnership with Synabs to create monoclonal antibodies and develop new diagnostic and theragnostic immunoassays.